Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways

Journal of Psychopharmacology

Volumn 27, Issue 11, 2013, Pages 1032-1043

  Monte, Aline Santos ^a   De Souza, Greicy Coelho ^a   McIntyre, Roger S ^b,c   Soczynska, Joanna K ^c   Dos Santos, Júnia Vieira ^a   Cordeiro, Rafaela Carneiro ^a   Ribeiro, Bruna Mara Machado ^a   De Lucena, David Freitas ^a   Vasconcelos, Silvânia Maria Mendes ^a   De Sousa, Francisca Cléa Florenço ^a   Carvalho, André Férrer ^a   Macêdo, Danielle S ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

cognition; ketamine induced model; Minocycline; prepulse inhibition; schizophrenia; social interaction

Indexed keywords

GLUTATHIONE; KETAMINE; MINOCYCLINE; NITRITE; PSYCHOTROPIC AGENT; RISPERIDONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; LOCOMOTION; MALE; MOUSE; NEGATIVE SYNDROME; NONHUMAN; OXIDATIVE STRESS; POSITIVE SYNDROME; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL INTERACTION;

COGNITION; KETAMINE-INDUCED MODEL; MINOCYCLINE; PREPULSE INHIBITION; SCHIZOPHRENIA; SOCIAL INTERACTION;

ANIMALS; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; CORPUS STRIATUM; DRUG THERAPY, COMBINATION; GLUTATHIONE; HIPPOCAMPUS; KETAMINE; MALE; MAZE LEARNING; MICE; MINOCYCLINE; MOTOR ACTIVITY; NITRIC OXIDE; NITRITES; PREFRONTAL CORTEX; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSORY GATING; SOCIAL BEHAVIOR; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84885779392     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113503506     Document Type: Article

References (77)

1. Archer J. Tests for emotionality in rats and mice: A review. Anim Behav. 1973 ; 21: 205-235
2. Arguello PA, Gogos JA. Cognition in mouse models of schizophrenia susceptibility genes. Schizophr Bull. 2010 ; 36: 289-300
3. Becker A, Grecksch G. Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Test of predictive validity. Prog Neuropsychopharmacol Biol Psychiatry. 2004 ; 28: 1267-1277
4. Behrens MM, Sejnowski TJ. Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?. Neuropharmacology. 2009 ; 57: 193-200
5. Bubenikova-Valesova V, Horacek J, Vrajova M, et al. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev. 2008 ; 32: 1014-1023
6. Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?. Acta Psychiatr Scand. 2007 ; 115: 93-100
7. Chatterjee M, Verma R, Ganguly S, et al. Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. Neuropharmacology. 2012 ; 63: 1161-1171
8. Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012 ; 26: 1185-1193
9. Chaves C, Marque CR, Trzesniak C, et al. Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: An update. Braz J Med Biol Res. 2009 ; 42: 1002-1014
10. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 ; 6: 797-801
11. Chindo BA, Adzu B, Yahaya TA, et al. Ketamine-enhanced immobility in forced swim test: A possible animal model for the negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012 ; 38: 310-316
12. Choi Y, Kim HS, Shin KY, et al. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology. 2007 ; 32: 2393-2404
13. Coyle JT. Nitric oxide and symptom reduction in schizophrenia. JAMA Psychiatry. 2013 ; 70: 664-665
14. Dall'igna OP, Fett P, Gomes MW, et al. Caffeine and adenosine a(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol. 2007 ; 203: 241-245
15. Dean OM, Data-Franco J, Giorlando F, et al. Minocycline: Therapeutic potential in psychiatry. CNS Drugs. 2012 ; 26: 391-401
16. De Oliveira L, Spiazzi CM, Bortolin T, et al. Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats. Prog Neuropsychopharmacol Biol Psychiatry. 2009 ; 33: 1003-1008
17. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A. 2001 ; 98: 14669-14674
18. Duan TT, Tan JW, Yuan Q, et al. Acute ketamine induces hippocampal synaptic depression and spatial memory impairment through dopamine D1/D5 receptors. Psychopharmacology. 2013 ; 228: 451-61
19. Fendt M, Koch M. Translational value of startle modulations. Cell Tissue Res. 2013 ;:
20. Fujita Y, Ishima T, Kunitachi S, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry. 2008 ; 32: 336-339
21. Garrido-Mesa N, Zarzuelo A, Galvez J. Minocycline: Far beyond an antibiotic. Br J Pharmacol. 2013 ; 169: 337-352
22. Geyer MA, Mcilwain KL, Paylor R. Mouse genetic models for prepulse inhibition: An early review. Mol Psychiatry. 2002 ; 7: 1039-1053
23. Green LC, Tannenbaum SR, Goldman P. Nitrate synthesis in the germfree and conventional rat. Science. 1981 ; 212: 56-58
24. Hallak JE, Maia-De-Oliveira JP, Abrao J, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: A randomized, double-blind, placebo-controlled trial. JAMA Psychiatry. 2013 ; 70: 668-676
25. Hashimoto K, Ishima T. A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: Translation initiation factor eIF4AI. PLoS ONE. 2010 ; 5: e15430
26. Hatta K, Sato K, Hamakawa H, et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr Res. 2009 ; 113: 49-55
27. Hou Y, Zhang H, Xie G, et al. Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental schizophrenic model in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2013 ; 17: 00072-00079
28. Inta D, Meyer-Lindenberg A, Gass P. Alterations in postnatal neurogenesis and dopamine dysregulation in schizophrenia: A hypothesis. Schizophr Bull. 2011 ; 37: 674-680
29. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991 ; 148: 1301-1308
30. Javitt DC, Zukin SR, Heresco-Levy U, et al. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull. 2012 ; 38: 958-966
31. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999 ; 20: 201-225
32. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006 ; 63: 1079-1087
33. Kamiyama H, Matsumoto M, Otani S, et al. Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway. Neuroscience. 2011 ; 177: 159-169
34. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-Ht(2) receptors - implications for models of schizophrenia. Mol Psychiatry. 2002 ; 7: 837-844
35. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007 ; 64: 633-647
36. Keilhoff G, Becker A, Grecksch G, et al. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and CFOS similar to those found in human schizophrenia. Neuroscience. 2004 ; 126: 591-598
37. Kraus RL, Pasieczny R, Lariosa-Willingham K, et al. Antioxidant properties of minocycline: Neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem. 2005 ; 94: 819-827
38. Kulak A, Cuenod M, Do KQ. Behavioral phenotyping of glutathione-deficient mice: Relevance to schizophrenia and bipolar disorder. Behav Brain Res. 2012 ; 226: 563-570
39. Larson MK, Walker EF, Compton MT. Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother. 2010 ; 10: 1347-1359
40. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: From pathophysiology to treatment. Ann N Y Acad Sci. 2003 ;: 138-158
41. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003 ; 160: 1209-1222
42. Levin R, Calzavara MB, Santos CM, et al. Spontaneously hypertensive rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapine. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35: 1748-1752
43. LevkovitzY (2013) Minocycline as an Adjunctive Therapy for Schizophrenia: A Randomized Controlled Study. Bethesda, USA: National Library of Medicine (US): ClinicalTrials.gov (Internet). Available at: http://clinicaltrials.gov/ show/NCT01133080 (accessed 24 July 2013).
44. Levkovitz Y, Levi U, Braw Y, et al. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res. 2007 ; 18: 154-162
45. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010 ; 71: 138-149
46. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: Efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007 ; 68: e04
47. Lorrain DS, Baccei CS, Bristow LJ, et al. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: Modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience. 2003 ; 117: 697-706
48. Lysaker PH, Erikson M, Macapagal KR, et al. Development of personal narratives as a mediator of the impact of deficits in social cognition and social withdrawal on negative symptoms in schizophrenia. J Nerv Ment Dis. 2012 ; 200: 290-295
49. Maia-De-Oliveira JP, Trzesniak C, Oliveira IR, et al. Nitric oxide plasma/serum levels in patients with schizophrenia: A systematic review and meta-analysis. Rev Bras Psiquiatria. 2012 ; 34: s149 - s155
50. Miyamoto S, Jarskog LF, Fleischhacker WW. Alternative pharmacologic targets for the treatment of schizophrenia: Results from phase I and II trials. Curr Opin Psychiatry. 2013 ; 26: 158-165
51. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009 ; 63: 257-265
52. Nandra KS, Agius M. The differences between typical and atypical antipsychotics: The effects on neurogenesis. Psychiatr Danub. 2012 ; 24: S95 - S99
53. Neill JC, Barnes S, Cook S, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism. Pharmacol Ther. 2010 ; 128: 419-432
54. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979 ; 95: 351-358
55. Peng Z, Zhang R, Wang H, et al. Ziprasidone ameliorates anxiety-like behaviors in a rat model of PTSD and up-regulates neurogenesis in the hippocampus and hippocampus-derived neural stem cells. Behav Brain Res. 2013 ; 244: 1-8
56. Radenovic L, Selakovic V. Differential effects of NMDA and AMPA/kainate receptor antagonists on nitric oxide production in rat brain following intrahippocampal injection. Brain Res Bull. 2005 ; 67: 133-141
57. Radyushkin K, Hammerschmidt K, Boretius S, et al. Neuroligin-3-deficient mice: Model of a monogenic heritable form of autism with an olfactory deficit. Genes Brain Behav. 2009 ; 8: 416-425
58. Remberk B, Namyslowska I, Rybakowski F. Cognition and communication dysfunctions in early-onset schizophrenia: Effect of risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2012 ; 39: 348-354
59. Schildknecht S, Pape R, Muller N, et al. Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem. 2011 ; 286: 4991-5002
60. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol. 2004 ; 74: 1-58
61. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem. 1968 ; 25: 192-205
62. Shamsi S, Lau A, Lencz T, et al. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res. 2011 ; 126: 257-264
63. Soczynska JK, Mansur RB, Brietzke E, et al. Novel therapeutic targets in depression: Minocycline as a candidate treatment. Behav Brain Res. 2012 ; 235: 302-317
64. Stojkovic T, Radonjic NV, Velimirovic M, et al. Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain. Prog Neuropsychopharmacol Biol Psychiatry. 2012 ; 39: 192-199
65. Takahata R, Moghaddam B. Glutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontal cortex. J Neurochem. 1998 ; 71: 1443-1449
66. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, 'Just the Facts' 4. Clinical features and conceptualization. Schizophr Res. 2009 ; 110: 1-23
67. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, 'Just the Facts' 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010 ; 122: 1-23
68. Torrey EF, Davis JM. Adjunct treatments for schizophrenia and bipolar disorder: What to try when you are out of ideas. Clin Schizophr Relat Psychoses. 2012 ; 5: 208-216
69. Tsai MC, Liou CW, Lin TK, et al. Changes in oxidative stress markers in patients with schizophrenia: The effect of antipsychotic drugs. Psychiatry Res. 2013 ; 13: 00044-00049
70. Van Den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: Pharmacology and methodology aspects. Schizophr Bull. 2010 ; 36: 246-270
71. West AR, Grace AA. Striatal nitric oxide signaling regulates the neuronal activity of midbrain dopamine neurons in vivo. J Neurophysiol. 2000 ; 83: 1796-1808
72. Wyatt RJ, Alexander RC, Egan MF, et al. Schizophrenia, just the facts. What do we know, how well do we know it?. Schizophr Res. 1988 ; 1: 3-18
73. Yamada K, Noda Y, Hasegawa T, et al. The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. J Pharmacol Exp Ther. 1996 ; 276: 460-466
74. Yee BK, Singer P. A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia. Cell Tissue Res. 2013 ;:
75. Zhang L, Kitaichi K, Fujimoto Y, et al. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry. 2006 ; 30: 1381-1393
76. Zhang L, Shirayama Y, Iyo M, et al. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology. 2007 ; 32: 2004-2010
77. Zhang XY, Zhou DF, Shen YC, et al. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology. 2012 ; 62: 1928-1934